What is Giotrif® (afatinib)?
Giotrif® (afatinib) is an irreversible ErbB Family blocker approved in more than 70 markets. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor EGFR mutation-positive (EFGR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.1
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Giotrif® and in India under the brand name Xovoltib®
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about Giotrif® (afatinib)?
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.1-4 For further details, please refer to the prescribing information.
References:
1. Giotrif® (afatinib) Thailand prescribing information.
2. Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
3. Wu YL et al. Lancet Oncol 2014;15(2):213–22.
4. Park K et al. Lancet Oncol 2016;17(5):577–89.